CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients
R Venegas-Rodriguez, B Santiesteban-Licea(Hospital Militar Central), Mónica Béquet‐Romero(Centro de Ingeniería Genética y Biotecnología), M. C. Domínguez-Horta(Centro de Ingeniería Genética y Biotecnología), Julio Baldomero(Centro de Ingeniería Genética y Biotecnología), Ortega-Gonzalez Lm(Instituto de Medicina Tropical “Pedro Kourí”), Gerardo Guillén(Hunan City University), R Santana-Sanchez, Ana R. García(Hospital Militar Central), LR Cruz(Hospital Militar Central), Mabel Hernández-Cedeño(Centro de Ingeniería Genética y Biotecnología), Ruben Peña-Ruiz, D Oliva-Perez(Hospital Militar Central), PR Aroche(Hospital Militar Central), G. Martínez-Donato(Centro de Ingeniería Genética y Biotecnología)
Cited by 7
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134